Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosyngen Opens Cell Therapy Production Facility in Guangzhou

publication date: Dec 29, 2021

Singapore's Biosyngen opened a cell therapy biological production base in China-Singapore Guangzhou Knowledge City (CSGKC). The $32 million facility will manufacture the company's CAR-T and TCR-T candidates, which are in early trials in  Singapore, China and Australia for nasopharyngeal cancer.  Phase I of the construction covers 10,000 square meters, which is the largest production facility for immune cells in Southern China, according to the company. The facility will comply with GMP standards and will feature fully-automated, fully-enclosed cellular drug production lines. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital